Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Your Next Event in Series:
Uncover the Biological Nuances of Gamma Delta T Cells to Inform your Translational Strategy including Targeting Specificity, Combination Strategies & Product Development to Confidently Progress to Clinical & Scalable Development for Patients in Need
Welcome to the 5th Gamma Delta T Therapies Summit
The Only Industry Gamma Delta T Cell-Specific Meeting That Ran This Year
The Only Industry Gamma Delta T Cell-Specific Meeting That Ran This Year
The 5th Gamma Delta T Therapies Summit returned to take a deep dive into the biological intricacies of gamma delta T cells, deciphering the rich landscape of targeted interventions and engineering, and exploit their unique pathways and mechanisms to create more effective therapeutics.
- IN8Bio - Detailed their autologous GDT product for GBM solid tumors, their allogeneic product for AML and their latest non-signaling CAR product
- Adicet Bio - Gave a Clinical Overview of both their oncology and autoimmune pipelines
- Acepodia - Informed Advantages of using Antibody-Cell Conjugation Technology in allogeneic therapies
- Immunocore - ImmTAX Platform to Gamma Delta T Cell Targets for the first approved TCR bi-specific therapeutic
- TC Biopharm - Outlined their clinical trial history with TCB008 and the Journey to a UK-based clinical trial: ACHIEVE
- Moffitt Cancer Center - Detailed unpublished new data on their allogeneic gamma delta immunotherapy for AML
What You Missed in 2024
- IN8Bio - Detailed their autologous GDT product for GBM solid tumors, their allogeneic product for AML and their latest non-signaling CAR product
- Adicet Bio - Gave a Clinical Overview of both their oncology and autoimmune pipelines
- Acepodia - Informed Advantages of using Antibody-Cell Conjugation Technology in allogeneic therapies
- Immunocore - ImmTAX Platform to Gamma Delta T Cell Targets for the first approved TCR bi-specific therapeutic
- TC Biopharm - Outlined their clinical trial history with TCB008 and the Journey to a UK-based clinical trial: ACHIEVE
- Moffitt Cancer Center - Detailed unpublished new data on their allogeneic gamma delta immunotherapy for AML
We Collaborated With IN8Bio, Adicet Bio, Acepodia, Takeda, Luminary Therapeutics, LAVA Therapeutics, OneChain Therapeutics
Brought together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward.
With a world-class speaker faculty, this meeting continued to be the one-stop shop to accelerate attendees' gamma delta T therapies.
2024 Speaker Faculty Included:
Our 2024 Partners:
Companies Attending Included:
